Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Costs of adverse drug events in German hospitals - a microcosting study.
Value Health 15, 868-875 (2012)
Objective: In Germany, only limited data are available to quantify the attributable resource utilization associated with adverse drug events (ADEs). The aim of this study was twofold: first, to calculate the direct treatment costs associated with ADEs leading to hospitalization and, second, to derive the excess costs and extra hospital days attributable to ADEs of inpatient treatments in selected German hospitals. Methods: This was a retrospective and medical record-based study performed from the hospitals' perspective based on administrative accounting data from three hospitals (49,462 patients) in Germany. Total treatment costs ("analysis 1") and excess costs (i.e., incremental resource utilization) between patients suffering from an ADE and those without ADEs were calculated by means of a propensity score-based matching algorithm ("analysis 2"). Results: Mean treatment costs ("analysis 1") of ADEs leading to hospitalization (n = 564) were (sic)1,978 +/- 2,036 (range (sic)191-18,147; median (sic)1,446; (sic)843-2,480 [Q1-Q3]). In analysis 2, the mean costs of inpatients suffering from an ADE (n = 1,891) as a concomitant disease or complication ((sic)5,113 +/- 10,059; range (sic)179-246,288; median (sic)2,701; (sic)1,636-5,111 [Q1-Q3]) were significantly higher ((sic)970; P < 0.0001) than those of non-ADE inpatients ((sic)4,143 +/- 6,968; range (sic)154-148,479; median (sic)2,387; (sic)1,432-4,701 [Q1-Q3]). Mean inpatient length of stay of ADE patients (12.7 +/- 17.2 days) and non-ADE patients (9.8 +/- 11.6 days) differed by 2.9 days (P < 0.0001). A nationwide extrapolation resulted in annual total treatment costs of (sic)1.058 billion. Conclusions: This is one of the first administrative data-based analyses calculating the economic consequences of ADEs in Germany. Further efforts are necessary to improve pharmacotherapy and relieve health care payers of preventable treatment costs.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Adverse Drug Events ; Cost Accounting ; Diagnosis Related Groups ; Hospitalization; PHYSICIAN ORDER ENTRY; LENGTH-OF-STAY; MEDICATION ERRORS; AMBULATORY-CARE; INTENSIVE-CARE; EXCESS LENGTH; ADMISSIONS; PREVENTABILITY; QUALITY; PREVENTION
ISSN (print) / ISBN
1098-3015
e-ISSN
1524-4733
Journal
Value in Health
Quellenangaben
Volume: 15,
Issue: 6,
Pages: 868-875
Publisher
Elsevier
Publishing Place
New York, NY
Reviewing status
Peer reviewed